Pensabene Licia, Cohen Marta C, Thomson Michael
Department of Paediatrics, Pugliese-Ciaccio Hospital, University "Magna Græcia" of Catanzaro, Catanzaro, Italy,
Curr Gastroenterol Rep. 2012 Jun;14(3):253-61. doi: 10.1007/s11894-012-0252-x.
Barrett's esophagus (BE) is a preneoplastic condition that predisposes to esophageal adenocarcinoma. Although data on the occurrence of BE in children are limited, recent studies have suggested an increase in the pediatric population. BE is thought to be a complex disease in which individual genetic predisposition interacts with environmental stimuli. Early premalignant clones produce biological and genetic heterogeneity, resulting in stepwise changes in differentiation, proliferation, and apoptosis, allowing disease progression under selective pressure. The value of endoscopic surveillance biopsy for dysplasia and carcinoma in patients with BE is controversial. Thus, the recognition of early and objective alternative risk markers, less susceptible of sampling error, will be of relevance in the management of BE patients. The possibility of performing molecular genetics on paraffin-embedded biopsies will expand our understanding of the natural history of BE and may lead to the use of biomarkers to inform treatment strategies.
巴雷特食管(BE)是一种癌前病变,易发展为食管腺癌。尽管关于儿童BE发病率的数据有限,但近期研究表明其在儿科人群中的发病率有所上升。BE被认为是一种复杂疾病,个体遗传易感性与环境刺激相互作用。早期癌前克隆产生生物学和遗传异质性,导致分化、增殖和凋亡的逐步变化,使得疾病在选择性压力下进展。内镜监测活检对BE患者发育异常和癌症的价值存在争议。因此,识别早期且客观的替代风险标志物,减少取样误差的影响,对于BE患者的管理具有重要意义。对石蜡包埋活检组织进行分子遗传学检测的可能性将拓宽我们对BE自然病史的理解,并可能促使使用生物标志物来指导治疗策略。